title: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.
abstract: Abstract   These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see  Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany. alkomiet.hasan@med.uni-muenchen.de
authors.forename: Alkomiet
authors.initials: A
authors.lastname: Hasan
authors.forename: Peter
authors.initials: P
authors.lastname: Falkai
authors.forename: Thomas
authors.initials: T
authors.lastname: Wobrock
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lieberman
authors.forename: Birte
authors.initials: B
authors.lastname: Glenthoj
authors.forename: Wagner F
authors.initials: WF
authors.lastname: Gattaz
authors.forename: Florence
authors.initials: F
authors.lastname: Thibaut
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001689:Biological Psychiatry / Q000379:methods*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D019317:Evidence-Based Medicine / Q000379:methods; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007391:International Cooperation; D008134:Long-Term Care; D008659:Metabolic Diseases / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy*; D012955:Societies, Medical
chemical_list: D014150:Antipsychotic Agents